Compare Campbell Soup Co. (CPB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Recursion Pharmaceuticals Inc — how do they compare? Campbell Soup Co. trades at $22.79 (market cap $6.69B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Campbell Soup Co. is far larger — about 3.8× Recursion Pharmaceuticals Inc's market cap, and Campbell Soup Co. pays a 6.96% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CPB | RXRX | |
|---|---|---|
Market Cap | $6.69B | $1.78B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $6.79 |
52-Week Low | $20.00 | $2.84 |
Enterprise Value | $13.29B | $1.30B |
Dividend Yield | 6.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $23.05, up 2.17% with a bullish technical signal. The company shows stable revenue around $10B but faces margin pressure with net income margin at 6.12%. Recent earnings beat expectations in Q1 2026, while analyst sentiment remains cautious with only 3.45% buy ratings. The stock offers a 6.8% dividend yield, supported by positive cash flow from operations of $1.13B in 2025.
The outlook remains mixed with cost-saving initiatives and product innovation providing upside potential, but persistent margin challenges and high debt levels pose significant risks. Current valuation appears reasonable with P/E of 11.29, though weak analyst consensus suggests limited near-term catalyst for price appreciation beyond dividend income.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
